Clinical trials: Histological Response
Sarcoma, Soft Tissue
Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS
This study is a phase IV post registration prospective observational feasibility study in patients with metastatic soft tissue sarcoma.
- Trial name
- PREDICT (NCT01995981)
- Testing
- Pazopanib
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 22 people
- Sponsor
- Radboud University Medical Center
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
To determine the anti-tumour activity and biological effects of cediranib (AZD2171) at a dose of 45mg, primarily in Gastrointestinal Stromal Tumour (GIST) patients who are resistant to imatinib mesylate (current standard therapy)…
- Trial name
- NCT00385203
- Testing
- AZD2171
- Where
- 2 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Follicular Lymphoma, Follicular Non-Hodgkin´s Lymphoma
Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy
Nowadays, therapy with monoclonal antibodies is considered to be a standard treatment that increases the rate of remissions and the overall survival in patients with follicular lymphoma.
- Conditions
- Follicular Lymphoma, Follicular Non-Hodgkin´s Lymphoma, Autologous Effector Lymphocytes
- Trial name
- NCT01329354
- Testing
- Autologous effector lymphocytes expanded ex-vivo
- Where
- Spain
- Volunteers
- 38 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Sarcoma, Rectal Carcinoma
Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay
THEODORA is a prospective pilot clinical trial aiming at first to evaluate and validate the predictive value of the A \& MS bioassays on tumor control by radiotherapy.
- Conditions
- Sarcoma, Rectal Carcinoma, Esophagus Cancer
- Trial name
- THEODORA (NCT02797405)
- Testing
- Standard treatment
- Where
- 7 sites in France
- Volunteers
- 97 people
- Sponsor
- Centre Leon Berard
Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML), Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL)
Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)
This study will evaluate a gene expression signature (Growth Factor Signature [GFS]) as a biomarker for response/resistance to BRC-ABL oncogene inhibitors.
- Trial name
- NCT00860535
- Testing
- Comparator: Biomarker evaluation
- Volunteers
- 9 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
Trial of pIL-12/MK-3475 in Metastatic Melanoma
This is a multicenter, Phase II, open-label, 42-patient single-arm trial of intratumoral pIL-12 electroporation (EP) in combination with pembrolizumab in patients with melanoma. Patients will be evaluated in 2 parts.
- Trial name
- NCT02493361
- Testing
- Pembrolizumab, pIL-12
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Francisco
Leukemia
G-CSF in Stimulating Peripheral Stem Cells for Autologous Stem Cell Transplant in Treating Patients With Chronic Phase Chronic Myeloid Leukemia in Complete Remission
RATIONALE: Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored until transplant.
- Trial name
- NCT00233961
- Testing
- filgrastim
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
BCC - Basal Cell Carcinoma, Immune Response
Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas
The study aim is to assess the immunological and clinical response in basal cell carcinoma (BCC) treated with ablative fractionated laser (AFL) as monotherapy and compare with BCC treated with combination-therapy of AFL and the…
- Conditions
- BCC - Basal Cell Carcinoma, Immune Response, Immunotherapy, Ablative Fractionated Laser
- Trial name
- NCT04570683
- Testing
- Nivolumab 10 MG/ML, Ablative fractionated laser
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Bispebjerg Hospital
Squamous Cell Carcinoma of Head and Neck
Monitoring Blood Flow and Metabolic Activity in Malignant Tissue of Head and Neck Region
This study will investigate the ability of Lucerno Dynamics Lara sensor when placed on the palpable carotid artery (or femoral artery) to monitor blood flow following the injection of 18-FDG and to distinguish peak flow in tumor…
- Trial name
- NCT04266470
- Testing
- Lara Scan, PET/CT Scan - Pre-treatment and Post-treatment
- Sponsor
- Wake Forest University Health Sciences
Cancer
Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor
MEK113583 is a Phase II open-label, multi-site study to investigate the objective response rate, safety, and pharmacokinetics of GSK1120212 in subjects with BRAF mutation-positive melanoma who were previously treated with or…
- Trial name
- NCT01037127
- Testing
- GSK1120212
- Where
- 10 sites in United States, Australia
- Volunteers
- 97 people
- Sponsor
- GlaxoSmithKline
Leukemia
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to…
- Trial name
- NCT00016159
- Testing
- filgrastim, lintuzumab, arsenic trioxide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Primary Central Nervous System (CNS) Lymphoma
CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)
This is an international, prospective, multicenter trial with the aim of characterizing circulating tumor DNA (ctDNA) for early response assessment in PCNSL patients treated with standard of care (SOC) 1st line therapy with a…
- Trial name
- CAPCI (NCT06755619)
- Where
- 5 sites in Finland
- Volunteers
- 60 people
- Sponsor
- Nordic Lymphoma Group
Chronic Myeloid Leukemia
Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha
To investigate whether patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib)…
- Trial name
- NCT01073436
- Testing
- Discontinuation of therapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan Rogel Cancer Center
Melanoma
Metabolic Phenotypes in Melanoma
This is a single centre, correlative, longitudinal, biomarker study that aims to describe the metabolic features of human melanoma using mass spectrometry.
- Trial name
- MetaMel (NCT05570227)
- Testing
- [U-13C]Glucose Infusion
- Where
- Australia
- Volunteers
- 240 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Hepatocellular Carcinoma
New Diagnostic Criteria in the Evaluation Response to Ablation Treatment of Hepatocellular Carcinoma Nodules
Hepatocellular carcinoma (HCC) is a primary liver malignancy that typically develops in the setting of chronic liver disease with a cirrhotic background.
- Trial name
- CEUS_LR_TRA (NCT07272083)
- Testing
- Contrast-Enhanced Ultrasound
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hepatocarcinoma
11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE
Prospective exploratory study specifically investigating the diagnostic and predictive role of 11C-Choline PET/CT and DWI MRI for response assessment in patients affected by HCC and candidate to TARE.
- Trial name
- NCT02519075
- Testing
- No intervention
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Istituto Clinico Humanitas
Localized Osteosarcoma, Metastatic Osteosarcoma
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
This randomized phase III trial is studying combination chemotherapy followed by surgery and two different combination chemotherapy regimens with or without PEG-interferon alfa-2b to compare how well they work in treating…
- Trial name
- EURAMOS-1 (NCT00134030)
- Testing
- Cisplatin, Doxorubicin Hydrochloride, Etoposide
- Where
- 218 sites in United States, Australia and 4 more
- Volunteers
- 1,334 people
- Sponsor
- Children's Oncology Group
Neuroendocrine Tumors, Carcinoid Tumors
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors.
- Conditions
- Neuroendocrine Tumors, Carcinoid Tumors, Neuroblastoma, Medulloblastoma
- Trial name
- GA-68 (NCT01619865)
- Testing
- 68Ga-DOTATOC PET/CT
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- Sue O'Dorisio
Non Small Cell Lung Cancer, Mesothelioma
Dose Individualization of Pemetrexed - IMPROVE-III
Rationale: Pemetrexed is a multi-targeted folate antagonist, which is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) and mesothelioma.
- Trial name
- IMPROVE-III (NCT03655834)
- Testing
- Pemetrexed
- Where
- 5 sites in Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Breast Cancer, Cutaneous Melanoma
A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope)
Feasibility study for a method allowing identification of tumor mutated epitopes in patients with breast cancer or cutaneous melanoma, and quantification of CD8+ T cells specific for these tumor neo-antigens in their lymph nodes
- Trial name
- NeoEpitope (NCT02831634)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Institut Curie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.